SCHEMBL22093047

SCHEMBL22093047

[CH2]CON1CCCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL445431 0.97
SCHEMBL28724717 0.74
SCHEMBL2127212 0.72
SCHEMBL31756591 0.71
SCHEMBL16411840 0.71
SCHEMBL740948 0.71
SCHEMBL2264282 0.71 MGLL (0.31)
SCHEMBL464983 0.70 MAPT (0.37)
Hydrochloric Acid SCHEMBL4435690 0.69
SCHEMBL6559537 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240173326-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR IDEAYA BIOSCIENCES, INC. 2024-05-30 US disclosed
EP-4370522-A1 ALKYLIDENE DERIVATIVES AS KRAS INHIBITORS Nikang Therapeutics, Inc. (US) 2024-05-22 EP disclosed
CN-117980310-A Alkylene derivatives as KRAS inhibitors 尼坎治疗公司 2024-05-03 CN disclosed
EP-4351570-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR Ideaya Biosciences, Inc. (US) 2024-04-17 EP disclosed
EP-4347569-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR Ideaya Biosciences, Inc. (US) 2024-04-10 EP disclosed
US-20240108626-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR IDEAYA BIOSCIENCES, INC. 2024-04-04 US disclosed
CN-117715893-A Combination therapy comprising a MAT2A inhibitor and a PRMT type II inhibitor 伊迪亚生物科学公司 2024-03-15 CN disclosed
CN-116903613-A 2-oxo quinazoline five-membered heterocyclic derivative, preparation method and application thereof 深圳微芯生物科技股份有限公司 2023-10-20 CN disclosed
CN-116283799-A Quinazoline methionine adenosyltransferase 2A inhibitors 南京正大天晴制药有限公司 2023-06-23 CN disclosed
WO-2023086934-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TAXANE IDEAYA BIOSCIENCES, INC. (US) 2023-05-19 WO disclosed
WO-2022256806-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR IDEAYA BIOSCIENCES, INC. (US) 2022-12-08 WO disclosed
WO-2022256808-A1 COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND TYPE I PRMT INHIBITOR IDEAYA BIOSCIENCES INC. (US) 2022-12-08 WO disclosed
CN-115260187-A Pyridone compounds and uses thereof 武汉人福创新药物研发中心有限公司 2022-11-01 CN disclosed
CN-115215862-A Pyrimidone compounds and uses thereof 武汉人福创新药物研发中心有限公司 2022-10-21 CN disclosed
EP-3894396-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Ideaya Biosciences, Inc. (US) 2021-10-20 EP disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 US disclosed
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-08-10 US disclosed
CN-113166078-A 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2021-07-23 CN disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 US disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 WO disclosed